Novel Polygodial Analogs to Treat Cancer

Tech ID:

Novel polygodial analogs for the treatment of cancer and other proliferative diseases have been developed by researchers at UT Health San Antonio. These analogs are effective in inhibiting cell proliferation both in vitro and in vivo, without the observable side effects attributed to the parent compound. Moreover, these analogs may have potential anti-tumor effects for chemo-resistant and/or inoperable solid tumors.



Progress in mitigating oral cancer has been very slow during the last 30 years, with the death rate for advanced oral cancer being as high as 70%. Most patients have advanced disease at the time of diagnosis, and surgical intervention often leaves the patient with severe cosmetic and functional consequences.


Polygodial analogs (which have to date never been developed for the treatment of cancer) could potentially represent an entirely new class of anti-tumor drugs. The polygodial analogs have high solubility, potency, and efficacy. The inventors have synthesized 9 novel polygodial analogs that exhibit potent anti-proliferative activity in vitro against oral cancer cell lines and in a number of other cell lines (including breast, prostate, and glial cancer cell lines) that are resistant to conventional chemotherapy. In vivo testing is complete on one analog, which demonstrated significant anti-tumor activity in an oral cancer OSCC xenograft mouse model. The MOA is believed to be the inhibition of the electron transport system resulting in ROS production and subsequent apoptosis.


Currently, the analogs under investigation are administered via intra-tumor injection. In vivo testing is continuing on the remaining analogs.


Commercial Applications & Advantages:

These polygodial analogs would be lucrative for pharma companies focusing on targeted therapy as they have the following advantages:

  • Cure or retard the progression of a variety of solid tumors and chemo-resistant cancers that currently do not have any effective treatment
  • Treat tumors without cosmetically and functionally deleterious surgical procedures
  • Reduce size of inoperable tumors, thereby giving the palliative patient more treatment options
For information contact:
John Fritz
Sr. Business Development Manager
Cara Gonzales
Alex Kornienko
Ramesh Dasari
Patent Information:

United States - Utility

Patent No.

Status: Pending

Europe - National Phase

Patent No. 

Status: Pending